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Abstract The aim of this study was to construct a promoter
containing DNA motifs for an endogenous transcription
factor associated with inflammation along with motifs for
pharmacological regulation factors. We demonstrate in
transfected cells that expression of a gene of interest is
induced by hypoxic conditions or through pharmacological
induction, and also show pharmacological repression. In
vivo studies utilised electroporation of plasmid to mouse
paws, a delivery method shown to be effective by
bioluminescence imaging. For gene therapy, the promoter
was used to drive expression of IL-1Ra in a paw
inflammation model with therapeutic effect observed which
was further enhanced when the promoter was additionally
induced with a pharmacological activator. One of the most
important observations from this study was that promoter
induction by hypoxia or inflammation could be prevented
by the pharmacological repressor in the absence of
doxycycline. These studies demonstrate that hybrid
promoters enable pharmacological adjustment to the path-
ophysiological level of gene expression and, importantly,
that they allow termination of gene expression even in the
presence of pathophysiological stimuli.
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Introduction
Gene therapy has started to prove effective in the treatment
of monogenic diseases through both ex vivo and in vivo
modification of cells [1, 2]. With our increasing confidence
in the effectiveness and safety of gene therapy, it has the
potential to be utilised for the treatment of polygenic
diseases where existing biological treatments could be
delivered by improved strategies and in a more cost-
effective manner. One of the major advantages of gene
therapy is the potential for local treatment of disease. By
delivering vectors or engineered cells at disease sites,
therapeutic proteins can be produced at their site of action,
thus minimising systemic side effects. Strategies for local
treatment could be further optimised by harnessing changes
in the disease process to directly control the gene therapy.
This could be achieved by harnessing changes in transcrip-
tion factor activation associated with the disease to drive
expression of a therapeutic molecule [3]. This type of gene
expression system is being examined in several disease
models including inflammation and cancer [4–9]. These
expression systems have the potential to link expression
levels of therapeutic molecules to the level of disease
activity which would be particularly useful in conditions
where there are periods of remission and relapse such as
multiple sclerosis and rheumatoid arthritis (RA). A poten-
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tial disadvantage of this approach could be insufficient
expression of therapeutic molecules or dysregulated or
inappropriate expression in response to a second pathology.
An alternative would be to combine a disease responsive
expression system with a pharmacologically regulated
system so that expression from a disease responsive
component could be switched ‘off’ or enhanced through
pharmacological control.
Hypoxic responsive gene regulation systems are dependent
on the fact that under normoxic conditions, the transcription
factor hypoxia-inducible factor-1 alpha (HIF-1α) is rapidly
degraded by the proteasome pathway [10]. Under hypoxic
conditions, HIF-1α is stabilised and forms a heterodimeric
transcription factor with the constitutively expressed HIF-1β,
which is able to bind to a DNA motif (RCGTG) known as
the hypoxia response element (HRE) located in the enhancer
region of several genes including vascular endothelial
growth factor and erythropoietin. Several studies have shown
that repeats of the HRE can be positioned upstream of a
minimal promoter element and selectively induce gene
expression in response to hypoxic stimulation [11–14].
Gene expression can also be regulated using a variety of
synthetic systems that are responsive to pharmacological
induction [15]. The tetracycline system has the advantage of
being responsive to antibiotics that have defined pharmaco-
kinetics and are known to be safe for in vivo use. The
tetracycline system [16] has undergone considerable devel-
opment for gene therapy application. Pharmacological
regulation would enable the physician to regulate gene
expression in response to clinical symptoms of a disease.
Others have shown that the tetracycline operon remains
functional when incorporated into a tissue-specific promot-
er [17], so we thought it would be feasible to combine
disease-regulated and pharmacologically regulated gene
expression systems in a single unit that could be utilised
in a gene therapy application. The disease process would
induce gene expression from the system. In the event that
expression levels were too low, therapeutic levels could be
achieved through additional pharmacological promoter
induction. Alternatively, if expression levels were too high,
or adverse effects were observed, expression could be
reduced or shut down through pharmacological repression.
Here, we design and construct a hybrid promoter system
that responds to physiological and pharmacological regula-
tion with these characteristics.
Materials and methods
DNA and cells
Plasmid DNA was propagated in DH5α and DH21
Escherichia coli and was purified using the Qiagen Endo-
Free Mega Kit (Qiagen Ltd., Crawley, West Sussex, UK).
Standard vectors used in this study include pGL3-basic and
pRL-CMV (Promega Corp., Madison, WI, USA) and
pcDNA3 (Invitrogen, Leek, The Netherlands). The vectors
pUHDrtTA2S-M2 [18] encoding rtTA2S-M2 and pCMV-
tetR(B/E)-KRAB [19] encoding tetR-KRAB were gifts
from Prof. W. Hillen (Institute for Microbiology, Erlangen,
Germany). The plasmids pcLuc+ [20], pGsmCMV, pGtL
[21] and pMIK (encoding both rtTA2S-M2 and tetR(B/E)-
KRAB from a constitutive promoter) [22] have been
previously described. Cell lines used were a human
fibrosarcoma cell line HT 1080 (ECACC ref no.
85111505) and the human embryonic kidney epithelial cell
line 293T. Cells were routinely cultured in DMEM
(BioWhittaker, Wokingham, UK) supplemented with pen-
icillin (100 U/ml)(BioWhittaker), streptomycin (100 μg/ml)
(BioWhittaker), glutamine (2 mM) (BioWhittaker) and 10%
foetal bovine serum (GibcoBRL, Paisley, UK).
Cloning
A 39-bp smCMV promoter equivalent to −52 to −14 of the
wild-type promoter [23] was cloned into pGL3-Basic
forming the vector pGL3smCMV. The HRE derived from
the human VEGF gene was constructed by annealing sense
5 ′ TCGAGACACAGTGCATACGTGGGTTTCCA
CAGGTCGTCTCACTCCCCGCCAG 3′ and antisense 5′
TCGACTGGCGGGGAGTGAGACGACCTGTG
GAAACCCACGTATGCACTGTGTC 3′ oligonucleotides
(Invitrogen) containing a 5′ Xho I site and a 3′ Sal I site (HRE
motif in bold). Four repeats of the HRE were first cloned into
the vector pGL3smCMV restricted with Xho I generating the
plasmid pH-Luc. The hybrid promoter PTH containing tetO
and HRE repeats was constructed by removing the four
repeats of the HRE by restriction with Sma I and Hind III
and inserting them into pGtL restricted with Stu I and Hind
III forming the construct pTH-Luc. The PTH promoter has
transcriptionally responsive elements in a compact arrange-
ment, with the tetO repeats located adjacent to elements
responsive to hypoxia by a distance of 74 nucleotides.
Human IL-1Ra was removed from the retroviral vector
MFG-IRAP (gift from P.D. Robbins, University of Pittsburgh,
USA) and cloned into pcDNA3 digested Bam HI–Xho I
creating the plasmid pcIL-1Ra. Then, IL-1Ra was removed
from pcIL-1Ra with Hind III and Xba I and cloned into
pH-Luc restricted with Hind III–Xba I, to give the vector
pH-IL-1Ra. IL-1Ra was also cloned into the hybrid promoter
vector pTH-Luc, restricted Hind III–Eco RV to remove
luciferase and generate the construct pTH-IL-Ra.
Promoter constructs were confirmed by DNA sequencing
(Advanced Biotechnology Centre, London, UK) and/or
restriction digests. Vectors are depicted schematically in
Fig. 1.
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Transient transfection
Transient transfections were performed using the calcium
phosphate precipitation method previously described [24].
Cells were plated on 12-well plates at a density of 1 to 5.0×
105 cells per well. After overnight culture, cells were
transfected with 1 to 5 μg of DNA. In experiments measuring
firefly luciferase, the vector pRL-CMV encoding Renilla
luciferase was also included as a control for transfection
efficiency and cells were stimulated 24 h after transfection.
Pathophysiological and pharmacological gene
induction in vitro
Induction of luciferase gene expression was performed by
incubation of cells with hypoxia (0.1% oxygen) in a Galaxy R
CO2 incubator (RS Biotech, Irvine, Ayrshire, Scotland).
Experiments monitoring expression of IL-1Ra at different O2
concentrations were performed by collecting media from cells
after incubation at each O2 concentration before adding fresh
media and then placing the cells in the next oxygen
concentration. Incubation time at each oxygen concentration
was between 6 and 16 h, and expressed IL-1Ra was calculated
per hour at each O2 concentration. Expression under the
control of the tetracycline inducible ‘on’ system utilised
doxycycline (Dox) (Sigma-Aldrich Co. Ltd, Dorset, UK).
IL-1Ra ELISA
The human IL-1Ra ELISA utilised an antibody pair from
R&D systems (Minneapolis, MN, USA; MAB280 at a
concentration of 4 μg/ml and BAF280 at a concentra-
tion of 200 ng/ml). A standard ELISA protocol was
used, and absorbance measurements were performed at
450 nm using a Tecan Genios microplate reader (Tecan
Group Ltd, Männedorf, Switzerland) with Magellan 4
software. The detection limit of this ELISA was
10–100 pg/ml human IL-1Ra.
Dual luciferase assay
The dual luciferase assays was obtained from Promega
(Promega Corp.), and the assay was performed according to
the manufacturer’s protocol with minor modifications.
Light emission was measured using an MLX Microtiter®
Plate Luminometer (Dynex Technologies Inc., Chantilly,
Virginia, USA).
In vivo delivery of plasmid to mouse paws
Mice were treated according to approved Home Office and
Institutional guidelines. Mice were treated with the muscle
relaxant Hypnorm™ (Janssen Animal Health, Jansen
Pharmaceuticals, Belgium) by i.p. injection and then
anaesthetised with halothane (Concord Pharmaceuticals
Ltd, Essex, UK) or AErrane (isofluorane, Baxter Healthcare
Ltd, Thetford, Norfolk) using Boyle’s apparatus (British
Oxygen Company, London, UK). Plasmid DNA (20 μg)
prepared in 50 μl saline was delivered by intraplantar (i.pl.)
injection. Electroconducting ultrasound gel (Henleys Med-
ical, Welwyn Garden, Herts, UK) was then applied to upper
and lower surfaces of the paw before electroporation
(200 V/cm/20 ms/2 Hz/4 pulses repeated four times with
reversal of polarity) was performed using a BTX Electro
Square Porator ECM 830 (BTX Instrument Division
Harvard Apparatus Inc. Holliston, MA) and caliper electrodes
384L (Harvard Apparatus Inc.).
Non-invasive bioluminescent imaging
Imaging was performed as previously described [25]. When
mice were repeatedly imaged, the same image settings were
used on each occasion. Images were captured and analysed
using Living Image® software v2.5.50.1 (Caliper Life
Sciences Corp., Hopkinton, MA, USA).
Antigen-induced paw inflammation
Male BALB/c mice (9 weeks old) were treated with
Hypnorm™ or were anaesthetized with isofluorane and were
then immunized with methylated bovine serum albumin
(mBSA) (100 μg) (Sigma-Aldrich Company Ltd.) emulsified
with complete Freund’s adjuvant and injected i.d. at the tail
base. Eight or 12 days later, groups of four to five mice were
Fig. 1 Schematic representation of expression constructs generated and
utilised in this study. Expressed genes are firefly luciferase targeted to
peroxisomes (grey rectangle) or cytoplasm (black rectangle) and IL-1Ra
(white rectangle). Promoter and response elements included the wild-
type and the small minimal CMV promoters (large and small black
ovals, respectively), the tetO (small white rectangles) and the HRE
(white ovals). Polyadenylation signals are indicated by a small triangle
and a 3′ untranslated region as a small black rectangle
J Mol Med (2012) 90:401–411 403
injected with plasmid (20 or 100 μg) in both paws by the
procedure described above. On day 14, baseline paw
thickness was measured using POCO 2T calipers (Krœplin
Längenmesstechnik, Schlüchtern, Germany) and some mice
were imaged using the IVIS 100 system (Caliper Life Sciences
Corp.). Then, mBSA (50 μg in 50 μl saline) was injected in
both paws or only the left whilst 50μl saline was injected in the
right paw. Measurement of paw thickness and bioluminescent
imaging were repeated on subsequent days.
Statistical methods
Significant differences were calculated using the Student’s
t test (Microsoft Excel 97, Microsoft Corp., Redmond, WA,
USA).
Results
Promoter responsiveness to hypoxic induction
In the vector pH-IL-1Ra, the human IL-Ra gene is
expressed from the PH promoter composed of four HRE
repeats and a minimal CMV promoter. This plasmid was
used to examine the sensitivity of the PH promoter to
stimulation with decreasing oxygen concentrations from
8% down to 0.1% in transiently transfected 293T cells (1×
105 cells/well on 12-well plates). These studies showed that
the PH promoter was minimally responsive to 8% O2 but
was significantly activated at O2 concentrations of 5% (p<
0.05) and 0.1% (p<0.05). At an O2 concentration of 0.1%,
the expression of IL-1Ra from the PH promoter was
1.66 ng/h/ml, which was 43% as active as the constitutive
CMV promoter in the construct pcIL-1Ra (3.8 ng/h/ml)
(Fig. 2a). We then examined the function of the PTH
promoter in the vector pTH-IL-1Ra in transfected 293T
cells (1×105 cells/well on 12-well plates) over a range of
O2 concentrations and observed similar induction character-
istics as the PH promoter with a threshold for activation
below 8% O2 and with maximal activation at 0.1% O2
(Fig. 2b). When activated with 0.1% O2, the PTH was 30%
as active as the CMV promoter.
Responsiveness of the hybrid PTH promoter
to physiological and pharmacological regulation
We then determined the effect of additional hybrid
promoter regulation through pharmacologically responsive
elements. The tetR-KRAB is a transcription repressor that
binds to the tetO sequence in the absence of Dox, and is
released from the tetO when Dox is present, whilst the
synthetic transactivator rtTA2S-M2 binds to the tetO
sequence in the presence of Dox. The effect of pharmaco-
logical repression and activation on the hypoxic response of
the PTH promoter was assessed in 293T cells by co-
transfection with the plasmids pTH-IL-1Ra and pMIK (that
encodes both the tetracycline repressor and activator). In
the absence of Dox, the PTH promoter was significantly
repressed by tetR-KRAB at all O2 concentrations tested
(Fig. 2b), and when cells were treated with Dox (1 μg/ml),
additional activation of the promoter was observed at all
levels of hypoxia (Fig. 2b).
In further experiments, the actions of the repressor and
activator on the PTH promoter were determined in
Fig. 2 Inducible gene expression from the PH and PTH promoters. The
PH promoter was assessed in 293T cells (125,000 cells/well in 12-well
plates) transiently transfected with pH-IL-1Ra (2 μg/well) and
sequentially cultured under increasingly hypoxic conditions from 8%
to 0.1% O2 (a). To assess the PTH promoter, 293T cells (1×10
5) on 12-
well plates were transfected with 1 μg of the plasmid pTH-IL-1Ra,
alone or co-transfected with 0.1 μg of pMIK. Cells were again
cultured in normoxic conditions or at gradually decreasing concen-
trations of O2 (b). Expression levels of IL-1Ra are presented as
picograms per millilitre per hour, and all values are the mean of
triplicate measurements±SEM. A significant difference of pe0.05
from the unstimulated and normoxic controls is indicated by a star
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isolation. In these experiments, HT 1080 cells were co-
transfected with the plasmid pTH-Luc encoding luciferase
along with plasmid encoding tetR-KRAB or rtTA2S-M2.
We saw low PTH activity under normoxic conditions in the
absence of Dox and at Dox concentrations of up to
100 ng/ml (Fig. 3a, white bars). When PTH activity was
examined under hypoxia (0.1% O2), we saw that tetR-
KRAB still repressed the PTH in the absence of Dox and
the repression was gradually reversed with increasing Dox
concentration (Fig. 3a, black bars). When activation by
rtTA2S-M2 was assessed under normoxic conditions,
pharmacological activation was evident from a Dox
concentration of 1 ng/ml and was further activated with
increasing Dox concentration (Fig. 3b, white bars). When
cells were stimulated with hypoxia, there was additional
promoter activation at all Dox concentrations (Fig. 3b,
black bars).
Plasmid delivery to mouse paws
Efficient transfection of mouse paws was achieved by i.pl.
injection of plasmid DNA followed by electroporation.
Using this method, luciferase expression from the plasmid
pcLuc+ was monitored by non-invasive bioluminescent
imaging 4 days after delivery (Fig. 4a) and expression was
maintained in the long term (present after 168 days, data
not shown).
Function of the hybrid promoter PTH at inflammatory sites
with co-expression of tetracycline regulatory molecules
The plasmids pTH-Luc and pMIK (10/10 μg) were
co-delivered to hind paws of mice immunized with mBSA
by i.pl. injection and electroporation. Groups of four mice
then received either sucrose sweetened water (10% w/v) or
Dox (20 μg/ml in sucrose sweetened water). On day 14,
mBSA was injected (i.pl.) into the left paw whilst saline
was injected as control in the right hind paw. Changes in
bioluminescence were monitored as a readout of promoter
activation (Fig. 4c). In mice that received Dox, there was
some basal promoter activity in both paws due to activation
by rtTA2S-M2; injection of mBSA caused a significant
induction of PTH promoter activity after 24 h in the
inflamed paw and a smaller non-significant increase in the
control paw. The higher induction in the inflamed paw is
similar to the in vitro experiments where higher induction
was observed with combined stimuli. In both paws,
promoter activity returned below baseline by 72 h
(Fig. 4d, e). By contrast, there was no basal or induced
expression of luciferase from the PTH promoter in paws of
mice that did not receive Dox (Fig. 4f, g), due to
tetR-KRAB repression.
The hybrid promoter format permits pharmacological
repression of disease-activated gene expression
The in vivo repression of the PTH promoter by tetR-KRAB
in isolation was assessed in another experiment. The
plasmids pTH-Luc and ptetR(B/E)-KRAB were co-
delivered to both paws on day 8 after mBSA immunisation.
One group of mice was treated with Dox (20 μg/ml in
sucrose sweetened water) for 3 days prior to mBSA
injection in the left paw. Prior to and after induction of
inflammation, bioluminescence was monitored by real-time
imaging (Fig. 5b). In mice that received Dox, there was a
significant induction of luciferase expression in the
inflamed left paw but not in the control paw (Fig. 5c, d).
In mice that did not receive Dox, the activation of the PTH
Fig. 3 Combined physiological and pharmacological regulation of
hybrid promoters. The plasmid pTH-Luc (2 μg) was co-transfected
with plasmid encoding the tetracycline repressor-tetR-KRAB
(2 μg; a)-or with plasmid encoding the tetracycline transactivator-
rtTA2S-M2 (2 μg; b)-along with pRL-CMV (0.5 μg) in to HT1080 cells.
Repression of the PTH promoter by tetR-KRAB is shown in a, and
pharmacological and hypoxic induction of the PTH promoter is shown
in b. Firefly luciferase values are corrected for Renilla luciferase
levels, and values are the mean of triplicate measurements±SEM.
Numbers at the top of the figures indicate the fold induction from the
non-induced control. A significant induction compared to the
normoxic control is indicated by a star (pe0.05)
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promoter was repressed in the inflamed paw (Fig. 5e, f).
This experiment clearly demonstrates the potential of
preventing disease-induced promoter activation with the
pharmacologically regulated repressor.
Therapeutic effects of IL-1Ra expressed constitutively
or from the PTH promoter in the antigen-induced paw
inflammation model
The same plasmid delivery approach was used to assess the
therapeutic effect of plasmids encoding IL-1Ra in an
antigen-induced paw inflammation model. Plasmid pcIL-
1Ra (100 μg) constitutively expressing IL-Ra was delivered
by i.pl. injection along with electroporation 12 days after
mBSA immunisation. Two days later, inflammation was
induced by i.pl. injection of the antigen mBSA. Increase in
hind paw thickness was significantly reduced in the mice
that received pcIL-1Ra compared with control mice that
received the control plasmid pcDNA3 (Fig. 6a). Expression
of IL-1Ra from the plasmid PTH-IL-1Ra (100 μg) was also
assessed in this model along with the effect of pharmaco-
logical repression and activation by co-administration of the
plasmid pMIK (10 μg). A significant inhibition in paw
thickness was observed in mice treated with pTH-IL-1Ra
alone and in those mice that received the plasmids pTH-
IL-1Ra+pMIK and were Dox-treated compared with
animals that were treated with pTH-IL-1Ra+pMIK but
were not given Dox (Fig. 6c).
Discussion
In this study, we have constructed a promoter responsive to
the transcription factor HIF-1α which plays a key role in
inflammation [26–28] and is demonstrated in RA tissue
[29]. The hypoxia-responsive promoter PH showed increas-
ing responsiveness to decreasing O2 concentration. The
promoter shows minimal activation under normoxic con-
ditions and at O2 concentrations down to 8% which is the
range of O2 tensions found in healthy tissue and the mild
hypoxia found in normal joints [30]. As O2 concentration
reduced from 5% to 0.1%, there is a concomitant increase
in promoter activity. This activity equates well to the
environment of RA joints where O2 levels below 5 mmHg
(less than 1% O2) have been measured which is caused by
reduced oxygen supply to the joint space [31, 32], and the
expression of HIF-1α has also been demonstrated in a
rodent model of paw inflammation [33]. In addition to
stabilisation of HIF-1α in response to hypoxia, it has also
been shown in response to cytokines (IL-1β and TNF-α)
[34–36], reactive oxygen species [37] and hormones [38].
A disadvantage of disease responsive promoters is the
lack of external control. Where promoters are responsive to
inflammation, inappropriate activation may occur in
response to inflammation associated with a second pathol-
ogy or infection. An alternative is to combine pharmaco-
logical and pathophysiological regulation in a single
system. A good example of this was reported by Payen
et al. [39], where they placed the expression of the
tetracycline transactivator molecule rtTA under the control
of a hypoxia-regulated promoter and expressed luciferase in
a second vector from a Ptet. In this arrangement, luciferase
expression is co-dependent on both hypoxia and Dox. We
have adopted a different strategy by directly incorporating
tetracycline responsive elements and disease responsive
elements in a hybrid promoter, which can be activated
independently by HIF-1α or pharmacologically (Dox)
through the tetracycline regulatory components (rtTA2S-
M2). These activation signals can be combined to give at
least additive promoter induction. When targeted with the
repressor tetR-KRAB, the promoter is turned ‘off’ in the
absence of Dox, even in the presence of activators of the
endogenous pathway. Importantly, in vivo experiments with
the PTH promoter clearly demonstrate that in the absence of
Dox, the promoter is actively repressed by tetR-KRAB, and
when Dox is administered, the repression is reversed and
the promoter responds to inflammation induction.
In previous gene therapy studies, systemic and local
expression of IL-1Ra has inhibited inflammatory responses
in several arthritis models; however, inflammation in
antigen-induced arthritis is more resistant to treatment with
IL-1Ra administered systemically as protein [40] and only
responds when local gene therapy is performed [41].
Therefore, the significant inhibition of inflammation
observed with both constitutive and regulated expression
of IL-1Ra was a clear demonstration of therapeutic effect.
When IL-1Ra was expressed from a regulated system, Dox
was administered by injection to ensure that animals
received sufficient Dox for promoter activation. The daily
injection of 500 μg is equivalent to the daily Dox intake
Fig. 4 Plasmid delivery to paws and PTH activity in inflammation.
Plasmid DNA pcLuc+ (20 μg) was delivered to the right paw of three
naïve DBA/1 mice by i.pl. injection followed by electroporation.
Expression of luciferase was monitored by non-invasive biolumines-
cent imaging on day 4 (a). To assess in vivo activity of the promoter
PTH an experiment was designed using bioluminescent imaging in an
antigen-induced paw inflammation model according to the tabulated
experimental plan (b). The plasmid pTH-Luc (10 μg) containing the
PTH promoter and pMIK (10 μg) encoding rtTA2
S-M2 and tetR-
KRAB were co-delivered to both paws of four BALB/c mice 10 days
after immunisation with mBSA. A group of four mice then received
Dox (20 μg/ml) in sucrose (10% w/v) sweetened drinking water whilst
a second group received sweetened water alone. Inflammation was
induced on day 14 in the left paw by injection of mBSA whilst saline
was injected in the right paw. Sequential images of luciferase activity
on day 0 and day 1 are illustrated in c for both groups, and mean
values±SEM for paw thickness (d and f) and bioluminescence (e and
g) are depicted. Significant changes from baseline values are indicated
by a star (pe0.05)
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that we have observed in previous gene therapy studies
using the tetracycline system where Dox was supplied as a
drink at a concentration of 200 μg/ml [20]. Inhibition of
inflammation was greater in the Dox-treated group due to
the fact that IL-1Ra expression was induced from the point
of Dox administration (day 13) prior to mBSA injection.
Whilst in the PTH-IL-1Ra group, expression would not be
induced until injection of antigen (day 14). As anticipated,
the inflammation was highest in the PTH-IL-1Ra+pMIK
group not treated with Dox where no therapeutic gene was
expressed.
The tetR-KRAB was first utilised to repress eukaryotic
gene expression by Deuschle et al. [42] who incorporated
tetO repeats into promoters such as CMV and were able to
repress constitutive gene expression with tetR-KRAB in the
absence of tetracycline. Upon addition of tetracycline, the
repression was reversed. The observations in our study
demonstrate pharmacological repression of physiologically
regulated promoters. This ability to shut down gene
expression in the absence of Dox provides a potential
mechanism to stop gene expression in the event of adverse
side effects which could be an important safety feature for
gene therapy in non-fatal human disease. In addition, in
chronic relapsing conditions such as RA, the approach
could be used to prevent long-term therapeutic gene
expression by restricting expression to periods of active
disease.
The bioluminescent assessment of promoter activation
demonstrated in this study is a useful tool because it
provides a real-time indication of promoter activity.
However, there are limitations of this approach as
sensitivity is affected by the spatial location and depth
in the tissue of the expressed luciferase protein. The
light signal is reduced by photons travelling a greater
distance through tissue, so inflammation, which
increases tissue thickness, will compromise the detection
of light and therefore lead to an underestimation in
promoter activation in these studies. Notwithstanding
these limitations, the bioluminescent studies have pro-
vided clear indication of promoter activation in vivo.
This study highlights the potential of expressing genes at
inflammatory sites in direct response to the disease process.
The ability to combine disease and pharmacological
regulation in a single promoter has advantages, especially
with regard to safety which will be important in any long-
term gene therapy for non-fatal chronic diseases.
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Fig. 5 Pharmacological repression of the PTH promoter. In order to
examine pharmacological repression of the PTH promoter by tetR-KRAB,
the plasmids pTH-Luc and pCMV-tetR(B/E)-KRAB were co-delivered to
both paws of BALB/c mice 8 days after mBSA immunisation (n=5 per
group). Dox containing (20 μg/ml) sweetened drinking water was
supplied to one group from day 11 and mBSA injected into the left
paw of both groups on day 14. Bioluminescence was measured prior to
mBSA injection (day 0) and at post-injection time points of day 1 and
day 3. This experimental plan is summarized in a and sequential images
obtained on days 0 and 1 for both groups are illustrated in b, whilst
changes in paw thickness (c and e) and quantified changes in
bioluminescence (d and f) are also illustrated. Significant changes from
baseline values are indicated by a star (pe0.05)
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Fig. 6 Effect of constitutive and regulated IL-1Ra expression in the
mouse antigen-induced paw inflammation model. a Plasmid pcDNA3 or
pcIL-1Ra (100 μg in 50 μl saline) were both delivered to six paws of
mBSA immunized mice on day 12. mBSA was injected into paws
2 days later, and inflammation was monitored by measurement of paw
thickness with calipers. The experimental plan to show gene therapy
with IL-1Ra expressed from the PTH promoter is summarized in b.
Plasmid DNA (100 μg) pTH-IL-1Ra, alone (grey bars) or in
combination with pMIK at a ratio of 10:1, was delivered by i.pl.
injection with electroporation in hind paws (n=8 for each group) on
day 12. On day 14, mBSA was delivered by injection into both hind
paws and Dox (500 μg daily i.p. injection) was delivered to one pTH-
IL-1Ra+pMIK group (white bars) whilst the other pTH-IL-1Ra+pMIK
group did not receive Dox (black bars) (c). Significant difference from
the pcDNA3 group or the pTH-IL-1Ra+pMIK-Dox group are indicated
by single star (pe0.05) and double star (pe0.01)
J Mol Med (2012) 90:401–411 409
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